GSM gold starGSM Global
中文版 · Chinese

JAMA SURMOUNT-ADOLESCENTS Trial on November 15: Among 160 Adolescents, BMI Fell a Mean 18.5 Percent at 72 Weeks on Tirzepatide Versus a 0.5 Percent Rise on Placebo

Monday, November 16, 2026 · Health · GSM News

JAMA published online on November 15 the results of SURMOUNT-ADOLESCENTS, a phase 3 randomized clinical trial of once-weekly subcutaneous tirzepatide in adolescents with obesity. The trial was conducted at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland and the United States from October 16, 2023, to June 2, 2026.

A total of 160 adolescents aged 12 years to younger than 18 years were randomized, 109 to tirzepatide and 51 to placebo, in addition to lifestyle counseling. Participants had obesity, or overweight with at least one obesity-related complication. At baseline the mean age was 14.6 years, 61.9 percent were female, mean body weight was 109.7 kg and mean body mass index (BMI) was 38.6. Tirzepatide was escalated every four weeks to a maximum tolerated dose of 5, 10 or 15 mg.

At week 72, the primary outcome showed a mean BMI reduction of 18.5 percent with tirzepatide, compared with a 0.5 percent increase with placebo, an estimated treatment difference of minus 19.0 percentage points. In the tirzepatide group, 79.6 percent achieved a BMI reduction of at least 5 percent, compared with 28.5 percent on placebo.

The paper, by Aaron S. Kelly and colleagues, was funded by Eli Lilly and registered on ClinicalTrials.gov as NCT06075667. JAMA's research summary notes that longer-term follow-up data are still needed. This report presents the trial results only and is not advice on medication for any individual.

Source: JAMA

Published by GSM · USA (original Chinese edition)

Photo: Wikimedia Commons, File:Tirzepatide structure.svg — Author: Vaccinationist. Licensing: Public domain.

Latest in Health